Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Swain

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Cancer Discovery|January 12, 2021
Targeting the p300/CBP Axis in Lethal Prostate CancerJonathan Welti, Adam Sharp, Nigel Brooks, et al.
European Urology|November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
The New England Journal of Medicine|October 29, 2015
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquin Mateo, Suzanne Carreira, Shahneen Sandhu, et al.
Nature Communications|October 8, 2025
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancerJuan M Jiménez-Vacas, Daniel Westaby, Ines Figueiredo, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Cancer Discovery|January 12, 2021
Targeting the p300/CBP Axis in Lethal Prostate CancerJonathan Welti, Adam Sharp, Nigel Brooks, et al.
European Urology|November 12, 2020
Advanced Prostate Cancer with ATM Loss: PARP and ATR InhibitorsAntje Neeb, Nicolás Herranz, Sara Arce-Gallego, et al.
The New England Journal of Medicine|October 29, 2015
DNA-Repair Defects and Olaparib in Metastatic Prostate CancerJoaquin Mateo, Suzanne Carreira, Shahneen Sandhu, et al.
Nature Communications|October 8, 2025
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancerJuan M Jiménez-Vacas, Daniel Westaby, Ines Figueiredo, et al.
Pageof 9